瑞卢戈利联合疗法对子宫内膜异位症相关疼痛女性功能与生活质量的影响
SPIRIT长期扩展研究纳入277例接受瑞卢戈利联合疗法(瑞卢戈利40 mg、雌二醇1 mg、炔诺酮醋酸酯0.5 mg)的绝经前子宫内膜异位症疼痛女性,EHP-30疼痛域评分在24、52、104周分别改善57.8%、66.4%、72.2%,非疼痛域及总分亦改善,痛经及非经期盆腔痛变化与EHP-30评分正相关。
要点
- 瑞卢戈利联合疗法治疗104周内EHP-30疼痛域评分持续改善。
- 24、52、104周分别有75.9%、83.6%、88.6%女性达临床意义改善。
- 痛经及非经期盆腔痛变化与EHP-30各域评分呈正相关。
核心结论
- 瑞卢戈利联合疗法在至多104周内持续降低子宫内膜异位症相关疼痛,并伴随功能与健康相关生活质量的改善。
研究设计与样本
- SPIRIT 3期试验的长期扩展研究,纳入完成随机SPIRIT试验的绝经前中重度子宫内膜异位症疼痛女性,所有女性接受瑞卢戈利联合疗法,报告至104周结果。
主要发现
- 277例接受瑞卢戈利联合疗法女性EHP-30疼痛域评分在24、52、104周分别改善57.8%(最小二乘均值变化-32.8;95%CI:-35.5,-30.1)、66.4%(-37.7;95%CI:-40.3,-35.0)、72.2%(-41.3;95%CI:-43.9,-38.7)。
- EHP-30疼痛域达临床意义改善的女性比例在24、52、104周分别为75.9%、83.6%、88.6%。
- EHP-30非疼痛域及总分同样改善,痛经及非经期盆腔痛变化与所有EHP-30域评分呈正相关。
- 延迟瑞卢戈利联合疗法组和安慰剂→瑞卢戈利联合疗法组结果相似。
关键数值与推荐
- 瑞卢戈利联合疗法方案为瑞卢戈利40 mg、雌二醇1 mg、炔诺酮醋酸酯0.5 mg。
- 延迟瑞卢戈利联合疗法为瑞卢戈利40 mg单药治疗12周,随后瑞卢戈利联合疗法12周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effect of relugolix combination therapy (relugolix CT; 40 mg relugolix, 1 mg estradiol, and 0.5 mg norethisterone acetate) for up to 2 years in the SPIRIT long-term extension study on functioning and health-related quality of life (QoL), using the Endometriosis Health Profile (EHP)-30 questionnaire, and assess how changes in QoL domains correlated with improvements in dysmenorrhea as well as nonmenstrual pelvic pain (NMPP). DESIGN: Long-term extension study of the SPIRIT phase 3 trials. SETTING: Clinics and University Hospitals. PATIENT(S): Premenopausal women with moderate-to-severe endometriosis pain who previously completed the randomized SPIRIT trials were eligible to enroll in an 80-week long-term extension where all women received relugolix CT. INTERVENTION(S): Relugolix CT (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg). MAIN OUTCOME MEASURE(S): Least squares (LS) mean changes in the EHP-30 domain and total scores from baseline (pivotal) were analyzed using a mixed-effects model. Results up to 104 weeks are reported by a pivotal trial treatment group with a focus on the relugolix CT group (i.e., relugolix CT or placebo for 24 weeks, or delayed relugolix CT [relugolix 40 mg monotherapy for 12 weeks, followed by relugolix CT for 12 weeks]). In addition, the relationships between changes in dysmenorrhea and NMPP as well as changes in EHP-30 scores were assessed. RESULT(S): In the 277 women treated with relugolix CT, LS mean EHP-30 pain domain scores improved by 57.8% (LS mean change: -32.8; 95% CI: -35.5, -30.1), 66.4% (LS mean change: -37.7; 95% CI: -40.3, -35.0), and 72.2% (LS mean change: -41.3; 95% CI: -43.9, -38.7) at weeks 24, 52, and 104, respectively. The proportions of women with clinically meaningful improvement in the EHP-30 pain domain were 75.9%, 83.6%, and 88.6% at weeks 24, 52, and 104, respectively. Non-pain EHP-30 domain and total scores likewise improved. A positive correlation between changes in dysmenorrhea/NMPP and all EHP-30 domain scores was observed. Results were similar for the delayed relugolix CT and placebo → relugolix CT groups. CONCLUSION(S): Sustained reduction of endometriosis-associated pain with relugolix CT observed up to 104 weeks was accompanied by improvements in functioning and health-related QoL. These findings complement the results of the pivotal SPIRIT trials, which showed that relugolix combination therapy significantly reduced dysmenorrhea, NMPP, and dyspareunia vs. placebo in premenopausal women with endometriosis-associated pain. CLINICAL TRIAL REGISTRATION NUMBER: Registration/clinicaltrials.gov identifier: SPIRIT Extension Study (NCT03654274).
引用
- As-Sanie S, Abrao MS, Reznichenko G, et al. Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain. Fertil Steril. 2024. PMID: 38906210. doi:10.1016/j.fertnstert.2024.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。